Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Borey and Sophia are among the first clients in Cambodia to begin long-acting injectable Cabotegravir (CAB-LA), a PrEP ...

HIV prevention pills are no different. The good news is PrEP (pre-exposure prophylaxis) is extremely effective and generally ...

Planned Parenthood of the Pacific Southwest has started offering an HIV prevention injection as part of its services, it was ...

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

Gilead Sciences' already dominant position in HIV pre-exposure prophylaxis (PrEP) could be extended if the FDA approves a new twice-yearly product later this year. The US regulator has started a ...